ONTARGET(R) Trial Proves Telmisartan Is As Protective As Ramipril And Better Tolerated In A Broad High-Risk … (Medical News Today)

The results of the landmark ONTARGET® Trial have proven that telmisartan, brand name Micardis®, a modern angiotensin II receptor blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisa